2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-184247
    SR-32685 2791469-14-0
    SR-32685 is a NAMPT activator and neuroprotective agent. SR-32685 enhances the enzymatic activity of hNAMPT, prevents intracellular NAD depletion, and protects neurons from death induced by toxic misfolded prion proteins. SR-32685 can be used in the research of protein misfolding neurodegenerative diseases and metabolic diseases.
    SR-32685
  • HY-184312
    PPAR agonist 8 1031072-40-8
    PPAR agonist 8 is an orally active pan-PPAR agonist, with KD values of 0.576 μM, 2.06 μM and 1.45 μM for PPARα, PPARγ and PPARδ, respectively. PPAR agonist 8 upregulates the expression of ATP-binding cassette transporter A1 (ABCA1) and promotes cholesterol efflux. PPAR agonist 8 reduces plasma cholesterol levels, decreases cholesterol accumulation in the liver and cholesterol deposition in pancreatic islets, regulates glucose and lipid metabolism, and causes no side effects of weight gain and obesity. PPAR agonist 8 can be used in the research of type 2 diabetes, hepatic steatosis and pancreatic islet dysfunction.
    PPAR agonist 8
  • HY-184324
    Anti-inflammatory agent 116 2975573-18-1 98%
    Anti-inflammatory agent 116 is an anti-inflammatory agent. Anti-inflammatory agent 116 binds to the p50 subunit and impairs the DNA-binding ability of the p65-p50 heterodimer. Anti-inflammatory agent 116 inhibits the abnormal activation of the NF-κB/MAPK signaling pathway. Anti-inflammatory agent 116 inhibits LPS-induced NO and MtROS production, IL-1β and TNF-α secretion, iNOS and COX-2 expression, phosphorylation of IKK, IκB, p65, p38, ERK and JNK, as well as nuclear translocation of p65. Anti-inflammatory agent 116 alleviates sepsis-associated acute liver injury in mice. Anti-inflammatory agent 116 can be used for the research of sepsis-associated acute liver injury.
    Anti-inflammatory agent 116
  • HY-184326
    DRAK2-IN-2 3080324-43-9
    DRAK2-IN-2 is a selective DRAK2 inhibitor with an IC50 value of 198.5 nM. DRAK2-IN-2 inhibits DRAK2-mediated phosphorylation of ULK1 at the Ser56 site. DRAK2-IN-2 enhances insulin secretion, increases mitochondrial membrane potential, alleviates Palmitic acid (HY-N0830)-induced mitochondrial membrane potential damage and Apoptosis, and improves glucose tolerance in vivo. DRAK2-IN-2 can be used for the research of type 2 diabetes.
    DRAK2-IN-2
  • HY-184340
    α-Glucosidase-IN-118 98%
    α-Glucosidase-IN-118 is a non-competitive inhibitor of α-glucosidase with a IC50 of 2.77 μM, and it shows no inhibitory activity against β-glucosidase. α-Glucosidase-IN-118 binds to the entrance of the α-glucosidase active site to block substrate release. α-Glucosidase-IN-118 can be used in the research of diabetes, obesity and lysosomal storage diseases.
    α-Glucosidase-IN-118
  • HY-184359
    RAS GTPase-IN-2 2252242-31-0
    RAS GTPase-IN-2 is a RAS GTPase inhibitor. RAS GTPase-IN-2 can be used in the research of cancer, ras-related autoimmune leukocytosis and certain types of mitochondrial dysfunction.
    RAS GTPase-IN-2
  • HY-185132
    RBP4-IN-2 3086854-73-8
    RBP4-IN-2 (Compound 14) is a RBP4 inhibitor. RBP4-IN-2 can reduce RBP4 in mouse plasma by more than 50%. RBP4-IN-2 can be used to study diseases where excessive lipofuscin accumulates in the retina.
    RBP4-IN-2
  • HY-185133
    RBP4-IN-3 3107328-23-1 98%
    RBP4-IN-3 (Compound 38) is a retinol-binding protein 4 (RBP4) inhibitor. RBP4-IN-3 can be used in studies related to cardiovascular diseases and obesity.
    RBP4-IN-3
  • HY-185306
    Morfamquat dichloride 4636-83-3
    Morfamquat dichloride (PP 745) is a bipyridine herbicide. Acute poisoning by Morfamquat dichloride strongly stimulates the reticuloendothelial system, causes lysosomal membrane damage and enzyme leakage, and interferes with the function of hepatocyte Golgi apparatus and related glucose metabolic pathways. Morfamquat dichloride significantly increases the activities of acid phosphatase and β-glucuronidase, exerting toxic effects on mice, while pre-administration of vitamin E alleviates such toxicity.
    Morfamquat dichloride
  • HY-185341
    PTERi 3114432-21-9 98.04%
    PTERi is a selective inhibitor of PTER with selectivity towards HDACs. PTERi increases the level of N-acetyltaurine in both lean and obese mice, and reduces food intake in obese mice. PTERi can be used in the research of obesity.
    PTERi
  • HY-185478
    NGD-4715 873318-96-8 98%
    NGD-4715 is an orally effective melanin-concentrating hormone receptor 1 (MCHR1) antagonist with IC50 and Ki values of 10.6 nM and 5.9 nM, respectively. NGD-4715 acts as an inhibitor of food intake, a body weight regulator and a metabolic regulator, and reduces food intake, body weight gain and blood glucose levels in diet-induced obese rats. NGD-4715 is applicable to obesity-related research.
    NGD-4715
  • HY-186011
    CPAG-1 2094991-62-3
    CPAG-1 is a small-molecule activator of progesterone receptor membrane component 2 (PGRMC2). CPAG-1 can enhance mitochondrial heme delivery to the nucleus mediated by PGRMC2 and activate genes related to heat production in brown adipose tissue (BAT), such as Ucp1 and Pgc-1α, and reduce lipid accumulation in BAT. CPAG-1 reduce fasting blood sugar and insulin levels, and improve glucose tolerance and insulin sensitivity. CPAG-1 can be used for research of type 2 diabetes.
    CPAG-1
  • HY-186084
    ACSL5-IN-4 3098298-20-2 98%
    ACSL5-IN-4 (the 9th compound in Table 115) is an ACS5 inhibitor, with its IC50 value for hACS5 being less than 100 nM. ACSL5-IN-4 can be used for research in digestive and oncological diseases.
    ACSL5-IN-4
  • HY-186104
    AMYR/CTR agonist 1 3097592-82-7 98%
    AMYR/CTR agonist 1 (Compound 195) is a pancreatic amylin receptor and calcitonin receptor (AMYR/CTR) agonist with EC50 values for pancreatic amylin receptor and calcitonin receptor cAMP of 99.5 and 6.16 pM respectively. AMYR/CTR agonist 1 can be used in the research of diseases such as type 2 diabetes and obesity.
    AMYR/CTR agonist 1
  • HY-186121
    Glucosylceramide synthase-IN-5 3118501-69-9 98%
    Glucosylceramide synthase-IN-5 (G3-3) is a glucosylceramide synthase (GCS) inhibitor that can be used for the study of the diseases and disorders associated with GCS activity, such as lysosomal storage disorders.
    Glucosylceramide synthase-IN-5
  • HY-186138
    TR modulator-1 1073180-47-8
    TR modulator-1 (compound 10c) is a selective thyroid hormone receptor (TR) modulator. TR modulator-1 can be used in the research of hyperthyroidism and thyrotoxicosis.
    TR modulator-1
  • HY-186155
    AMPK activator 19 1273323-44-6
    AMPK activator 19 (Compound 57), alkene oxindole derivative, is an AMPK activator. AMPK activator 19 can be used for the research of diseases that are related to AMPK regulation, such as obesity, dyslipidemia, hyperglycemia, type 1 or type 2 diabetes.
    AMPK activator 19
  • HY-186163
    CC-410 636564-27-7
    CC-410 is a selective Nicotinamide N-methyltransferase (NNMT) inhibitor with a human IC50 value of 1.6 µM. CC-410 impairs terminal adipocyte differentiation via glucocorticoid signaling network deregulation, inhibits adipogenesis and lipid accumulation with time-sensitive activity limited to early adipogenesis stages. CC-410 can be used for the researches of early-onset obesity, glucocorticoid-induced obesity.
    CC-410
  • HY-186172
    KS0365 1689577-22-7
    KS0365 is a selective TRPV3 agonist with an EC50 of 5.08 μM. KS0365 does not activate TRPV2 or TRPV4 channels. KS0365 triggers an increase in [Ca2+]i and accelerates keratinocyte migration. KS0365 can be used in studies related to impaired skin wound healing.
    KS0365
  • HY-186200
    PTHR1 antagonist 1 2458230-46-9 98%
    PTHR1 antagonist 1 is a PTHR1 antagonist with an IC50 of 0.090 µM. PTHR1 antagonist 1 is applicable to the research of calcium metabolism disorders.
    PTHR1 antagonist 1
Cat. No. Product Name / Synonyms Application Reactivity